Alnylam Pharmaceuticals, Inc. (LON:0HD2)
319.59
+3.71 (1.17%)
At close: Jun 27, 2025
Alnylam Pharmaceuticals Revenue
Alnylam Pharmaceuticals had revenue of $594.19M USD in the quarter ending March 31, 2025, with 20.20% growth. This brings the company's revenue in the last twelve months to $2.35B, up 17.21% year-over-year. In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B with 22.97% growth.
Revenue (ttm)
$2.35B
Revenue Growth
+17.21%
P/S Ratio
17.08
Revenue / Employee
$1.05M
Employees
2,230
Market Cap
31.03B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 419.95M | 22.97% |
Dec 31, 2023 | 1.83B | 790.87M | 76.23% |
Dec 31, 2022 | 1.04B | 193.13M | 22.88% |
Dec 31, 2021 | 844.29M | 351.43M | 71.31% |
Dec 31, 2020 | 492.85M | 273.10M | 124.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
Alnylam Pharmaceuticals News
- 12 days ago - Alnylam Pharmaceuticals Names Garg R&D Chief - Market Watch
- 12 days ago - Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer - Business Wire
- 22 days ago - Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire
- 25 days ago - Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case - Benzinga
- 4 weeks ago - Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field - Seeking Alpha
- 4 weeks ago - Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference - Business Wire
- 5 weeks ago - Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga
- 6 weeks ago - Alnylam Issues 2024 Corporate Responsibility Report - Business Wire